The pharmacokinetic and pharmacodynamic properties and short-term outcome of a novel once-weekly PEGylated recombinant human growth hormone for children with growth hormone deficiency.

Front Endocrinol (Lausanne) · 2022 · PMC9405430 · PMID 36034448

Europe PMC DOI

hedged sentence

0.0640

closest p · 1.3× alpha

0.0640

boldest claim

The sentences

an increasing trendp = 0.064so close (0.05 < p ≤ 0.1)

Compared to baseline, YPEG-rhGH 100 μg/kg/week group showed an increasing trend of HV ( p = 0.064), while the other 3 groups showed significant increases in HV ( p = 0.004 in YPEG-rhGH 140 μg/kg/week group, p < 0.001 in YPEG-rhGH 120 μg/kg/week group and the daily rhGH group) ( Figure 4A ).

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.